CN101327191A - Lactobionic acid azithromycin for injections and preparation method thereof - Google Patents
Lactobionic acid azithromycin for injections and preparation method thereof Download PDFInfo
- Publication number
- CN101327191A CN101327191A CNA2008101267461A CN200810126746A CN101327191A CN 101327191 A CN101327191 A CN 101327191A CN A2008101267461 A CNA2008101267461 A CN A2008101267461A CN 200810126746 A CN200810126746 A CN 200810126746A CN 101327191 A CN101327191 A CN 101327191A
- Authority
- CN
- China
- Prior art keywords
- lactobionic acid
- freeze
- acid azithromycin
- dried powder
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides lactose-azithromycin freeze-dried powder and a preparation method thereof. The freeze-dried powder with simple components only contains main drug component. The preparation method of the lactose-azithromycin freeze-dried powder is that main drug is dissolved in injection water, and then is decolorized and filtered through activated carbon, the filtrate is cooled at 30DEG below zero to 60DEG below zero in a freeze drier to be solidified, and then is heated to 0 DEG to 40 DEG by stages in the condition of high vacuum, meanwhile, freeze-drying curve is controlled strictly, and finally, the lactose-azithromycin freeze-dried powder is obtained. The obtained lactose-azithromycin freeze-dried powder has the advantages of favorable stability and resolubity, etc.
Description
Technical field
The present invention relates to a kind of lactobionic acid azithromycin for injections, relate to a kind of lactobionic acid azithromycin freeze-dried powder and preparation method thereof more specifically.
Background technology
Lactobionic acid azithromycin (Azithromycin Lactobionate) is a kind of macrolide antibiotics of semisynthetic assorted nitrogen fifteen-membered ring, and its chemical name is (2R, 3S, 4R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-(L-nuclear-own pyrans glycosyl) oxygen)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-seven methyl isophthalic acid 1-[(3,4,6-three deoxidations-3-(dimethylamino)-β-D-wood-own pyrans glycosyl) oxygen]-2 Lactobionates of 1-oxa--6-azacyclo-pentadecane-15 ketone, molecular structure is:
Azithromycin is to introduce NCH on the 9a of erythromycin lactone is
3The fifteen-membered ring class antibiotic that substituent methyl makes is because the change of chemical constitution makes medicine that antibacterial characteristics, pharmaco-kinetic properties and therapeutic effect preferably be arranged: stable to acid, antimicrobial spectrum and erythromycin are close, act on byer force, high bioavailability is arranged, untoward reaction is lacked than erythromycin and light, absorb rapidly, the 10-100 that surpasses serum-concentration at infection site tissue and IC doubly, the length of holding time was eliminated the half-life above 40 hours.That has developed is mainly oral formulations, and blood drug level is low, onset slow and the not high shortcoming of bioavailability but exist.Lactobionic acid azithromycin is the macrolide acylate that azithromycin and lactobionic acid form, and verified, this medicine has overcome former single free some major defects of alkaloid oral formulations, for clinical treatment provides more efficient drug and dosage form.
There are some researches show that all there are unstable factor in azithromycin and acid salt thereof, can cause it to tire as oxidation, hydrolysis etc. and reduce and lose antibacterial activity that local toxicity obviously increases as the murder by poisoning to liver.With azithromycin for example lactobionic acid azithromycin be prepared into the freeze-dried powder dosage form, it has rapid-action, bioavailability advantages of higher.
The preparation method of lactobionic acid azithromycin freeze-dried powder is disclosed in the Chinese invention patent application number 200710053154.7: get lactobionic azithromycin aqua compound (by anhydride), add pharmaceutically acceptable frozen-dried supporting agent or excipient, add injection and blunge and make dissolving, pharmaceutically acceptable acid-alkali accommodation pH is 5.5～7.5, adds active carbon 0.005～0.5% (W/V) and stirs 15～45min, filter, moisturizing, aseptic filtration, packing, lyophilization, tamponade gets finished product.Added proppant or excipient in this lactobionic acid azithromycin freeze-dried powder, performances such as the stability of principal agent, its related substances have been caused influence.
Summary of the invention
The purpose of this invention is to provide a kind of lactobionic acid azithromycin for injections freeze-dried powder and preparation method thereof, this lactobionic acid azithromycin does not contain any pharmaceutic adjuvant, low, the steady quality of moisture of the lactobionic acid azithromycin freeze-dried powder by this preparation method gained, advantage such as solubility is good.
Lactobionic acid azithromycin for injections freeze-dried powder of the present invention is made up of the active component lactobionic acid azithromycin.
Do not contain any adjuvant in the described lactobionic acid azithromycin freeze-dried powder, in drug prescription, use the adjuvant that kind is few, consumption is few in the pharmaceutical preparation as much as possible or even do not use adjuvant, avoid adjuvant to the active component Effect on Performance, the content of its related substance is increased, to place for a long time have insoluble matter to occur when causing dissolving, the side effect of also having avoided adjuvant to bring human body simultaneously, promptly adjuvant still less have still less incompatibility and the clinical drug safety of Geng Gao.
At patent application 200710053154.7 disclosed lactobionic acid azithromycin freeze-dried powders is to contain principal agent lactobionic acid azithromycin, xylitol, sodium dihydrogen phosphate and sodium hydrogen phosphate, obtains the lactobionic acid azithromycin freeze-dried powder through lyophilization.Compare with the lactobionic acid azithromycin freeze-dried powder described in the patent application 200710053154.7, have only the principal agent lactobionic acid azithromycin in the freeze-dried powder of the present invention, do not add any pharmaceutic adjuvant.
If in lactobionic acid azithromycin, do not add any adjuvant, the lyophilized formulations that adopts the freeze-drying method of prior art to make, defective such as profile is subsided, and solubility is very poor has only adjuvants such as the excipient of adding, just can obtain the product that outward appearance is full, solubility is good.And the present invention passes through the improvement to the freeze-dry process of lactobionic acid azithromycin freeze-dried powder, and making does not need to add adjuvant, and the every index of gained lactobionic acid azithromycin freeze-dried powder all meets the requirements.
For realizing purpose of the present invention, the preparation method of this lactobionic acid azithromycin freeze-dried powder is as follows:
(1) lactobionic acid azithromycin joined in the water for injection dissolve,
(2) add active carbon in the lactobionic acid azithromycin solution that step (1) obtains, aseptic filtration,
(3) with the filtrate lyophilization of step (2), promptly get the lactobionic acid azithromycin freeze-dried powder,
It is characterized in that described lyophilization is that filtrate ℃ is made it in freezer dryer internal cooling-30～-60 to solidify, and then under the fine vacuum, is warming up to 0～40 ℃ stage by stage, strict simultaneously control freeze-drying curve finally obtains the lactobionic acid azithromycin freeze-dried powder.
Step of the present invention (2) is described to add active carbon in lactobionic acid azithromycin solution, the temperature of its solution is at 0～10 ℃, its preferred 3～5 ℃.
The consumption of described active carbon is 0.20～0.30% (g/mL) of solution amount volume, its preferred 0.20～0.25% (g/mL).
The consumption of active carbon, holding temperature, temperature retention time are all influential to the content of principal agent lactobionic acid azithromycin, and experimental example 1 adopts orthogonal experiment method to filter out best parameter.
When the selection of research active carbon, the inventor finds at 15～20 ℃ of active carbons very little to lactobionic acid azithromycin absorption.
The inventor finds, at lactobionic acid azithromycin solution during at 0～10 ℃, use 0.20%～0.30% (g/mL) active carbon, this moment, there was adsorption in active carbon hardly to the principal agent lactobionic acid azithromycin, solution colour is a colorless cleared solution after filtering, and the lactobionic acid azithromycin after activated carbon adsorption carries out the detection of related substance, and its total impurities is below 1.90%, maximum contaminant is below 0.2%, and bacterial endotoxin is up to specification.Auspiciously see experimental example 1.
Above-mentioned described filter activity charcoal concrete steps are that first coarse filtration is taken off charcoal, with the microporous filter membrane fine straining of the filtrate after the coarse filtration with 0.22 μ m, puts into the freezer dryer drying then again.
Lyophilization control whether appropriately directly affect the every performance quality of freeze-dried powder, the present invention improves Freeze Drying Technique, makes every performance of gained lactobionic acid azithromycin freeze-dried powder exceed the result that those skilled in the art can predict.
Refrigerating process of the present invention is filtrate to be cooled to-30～-40 ℃ rapidly, makes it primary solidification, is cooled to-45～-60 ℃ again, keep-45～-60 ℃ freezing 3～5 hours, it is freezed fully.
In the solution refrigerating process, solution is quickly cooled to-30～-40 ℃ from room temperature, impel a large amount of nucleus of the easier formation of lactobionic acid azithromycin solution, the growth rate of ice crystal descends simultaneously, the final tiny ice crystals in a large number that form, lactobionic acid azithromycin is dispersed in the entire product regularly, thereby the highly meticulous small loose structure of whole appearance freezes product structure homogeneous, and resulting freeze-dried powder can keep original structure, the also corresponding raising of outward appearance exquisiteness, dissolution velocity.The inventor has done screening test to the refrigerating process of lactobionic acid azithromycin solution, sees experimental example 2 for details.Performance according to the freezing by different way lactobionic acid azithromycin freeze-dried powder that obtains of 2 pairs of lactobionic acid azithromycin solution of experimental example is tested, and the overall performance of its freeze-dried powder improves a lot.
In the above-mentioned lactobionic acid azithromycin freezing dry process, lactobionic acid azithromycin after freezing fully, behind the evacuation, the temperature of the lactobionic acid azithromycin that will freeze in 9～12 hours rises to-5～0 ℃, kept-5～0 ℃ of vacuum dryings 8～11 hours, continue to heat up, in 2～4 hours, rise to 30～35 ℃, kept 30～35 ℃ of vacuum dryings 6～7 hours.
The distillation phase after freezing is removed about 90% moisture, and the used time of sublimation temperature and distillation can have influence on the quality of product.Earlier the frozen product temperature was raised at 9～12 hours and is lower than eutectic point, kept this temperature afterwards 8～11 hours, the beginning drying layer is thinner, steam be easy to by, carrying out along with dry run, dried layer constantly thickens, and sublimation surface is dwindled, and required energy reduces gradually, comparatively speaking, the heat energy of supplying with increases gradually, and promptly cryogenic temperature moves closer to eutectic temperature, but does not reach eutectic temperature, simultaneously, the present invention is in the improvement of lactobionic acid azithromycin solution at refrigerating process, and forms uniform ice crystal structure, and what make that whole sublimation process steam constantly can be unobstructed passes through to do layer.Experimental example 3 is to sublimation temperature of the present invention, holds time and the screening experiment of rate of sublimation in sublimation temperature.
Promptly remove the process of bound water at dry period, behind sublimation drying, also remaining a part of adsorbed water and bound water, these water are not frozen, can not remove in sublimation drying.The present invention rose to 30～35 ℃ with temperature rapidly at 2～4 hours behind sublimation drying, heat up rapidly to help reducing the product residual moisture content and shorten drying time, and kept this temperature 6～7 hours.
The freeze drying process of the preferred lactobionic acid azithromycin freeze-dried powder of the present invention is: lactobionic acid azithromycin filtrate is cooled to-35～-38 ℃ rapidly, it is tentatively freezed, continue to be cooled to-55～-60 ℃ again, keep-55～-60 ℃ freezing 4～4.5 hours, it is freezed fully, evacuation, the temperature of the lactobionic acid azithromycin that freezed in 11～12 hours rises to-2～0 ℃, kept-2～0 ℃ of vacuum dryings 8～9 hours, continue to heat up, in 3～3.5 hours, rise to 30～35 ℃, kept 30～35 ℃ of vacuum dryings 6.5～7 hours.
Above-mentioned lactobionic acid azithromycin freeze-dried powder is indoor in the sterile working, takes by weighing the qualified aseptic lactobionic acid azithromycin of chemical examination by recipe quantity, and it is aseptic subpackaged in cillin bottle to press lactobionic acid azithromycin, and jumps a queue, rolls lid promptly.
Compare with the lactobionic acid azithromycin freeze-dried powder described in the patent application 200710053154.7, has only the principal agent lactobionic acid azithromycin in the freeze-dried powder of the present invention, do not add any pharmaceutic adjuvant, by improvement to the freeze-dry process of lactobionic acid azithromycin freeze-dried powder, make the crystallization of gained lactobionic acid azithromycin freeze-dried powder even, color and luster is consistent, profile is full; Contained humidity is lower than 0.7%, the steady quality of medicine, and dissolution velocity has also improved; Because the composition in the freeze-dried powder is single, make that operating procedure is simple, cost of material lowers greatly simultaneously.
The present invention is by improving greatly prepared lactobionic acid azithromycin freeze-dried powder stability of the improvement of lactobionic acid azithromycin freeze-dry process and dissolution velocity, other performances all meet the requirement of injection freeze-dried powder, freeze-drying prods of the present invention is done stability test, see experimental example 4 for details, analyze from this experimental example, stability improves greatly, places at normal temperatures 30 months, and every after testing index is constant substantially.
The specific embodiment
Further describe lactobionic acid azithromycin freeze-dried powder preparation process of the present invention below by instantiation, but be not limited to embodiment.
Embodiment 1
Lactobionic acid azithromycin finished product 250g is dissolved in the 1600mL water for injection, stirring makes its dissolving, add the 4.0g active carbon, keeping temperature is 5 ℃ of stirring decolourings 30 minutes, again through 0.45 μ m filtering with microporous membrane carbon removal, add the injection water again to 2000ml, fully stir and made the solution mix homogeneously in 20 minutes, the solution for preparing carries out filtration sterilization through the microporous membrane of 0.22 μ m.Last filtrate is put into the freeze dryer charging tray, be cooled to-38 ℃ rapidly, make its primary solidification, continue to be cooled to-55 ℃ again, keep-55 ℃ freezing 4 hours, it is freezed fully, evacuation, in 11 hours, gradually temperature is risen to-2 ℃, keep-2 ℃ of vacuum dryings 8 hours, and continued to heat up, in 3 hours, rise to 30 ℃, kept 30 ℃ of vacuum dryings 7 hours, the moisture in the lactobionic acid azithromycin freeze-dried powder that obtains is 0.54%.
Embodiment 2
Lactobionic acid azithromycin finished product 250g is dissolved in the 1600mL water for injection, stirring makes its dissolving, add the 3.2g active carbon, keeping temperature is 3 ℃ of stirring decolourings 30 minutes, again through 0.45 μ m filtering with microporous membrane carbon removal, add the injection water again to 2000ml, fully stir and made the solution mix homogeneously in 20 minutes, the solution for preparing carries out filtration sterilization through the microporous membrane of 0.22 μ m.Last filtrate is put into the freeze dryer charging tray, be cooled to-35 ℃ rapidly, make its primary solidification, continue to be cooled to-60 ℃ again, keep-60 ℃ freezing 4.5 hours, it is freezed fully, evacuation, in 12 hours, temperature is risen to 0 ℃ gradually, keep 0 ℃ of vacuum drying 9 hours, and continued to heat up, in 3.5 hours, rise to 35 ℃, kept 35 ℃ of vacuum dryings 6.5 hours, the moisture in the lactobionic acid azithromycin freeze-dried powder that obtains is 0.61%.
Embodiment 3
Lactobionic acid azithromycin finished product 250g is dissolved in the 1600mL water for injection, stirring makes its dissolving, add the 3.68g active carbon, keeping temperature is 8 ℃ of stirring decolourings 30 minutes, again through 0.45 μ m filtering with microporous membrane carbon removal, add the injection water again to 2000ml, fully stir and made the solution mix homogeneously in 20 minutes, the solution for preparing carries out filtration sterilization through the microporous membrane of 0.22 μ m.Last filtrate is put into the freeze dryer charging tray, be cooled to-30 ℃ rapidly, make its primary solidification, continue to be cooled to-50 ℃ again, keep-50 ℃ freezing 5 hours, it is freezed fully, evacuation, in 9 hours, gradually temperature is risen to-5 ℃, keep-5 ℃ of vacuum dryings 11 hours, and continued to heat up, in 2 hours, rise to 30 ℃, kept 30 ℃ of vacuum dryings 6 hours, the moisture in the lactobionic acid azithromycin freeze-dried powder that obtains is 0.70%.
Embodiment 4
Lactobionic acid azithromycin finished product 250g is dissolved in the 1600mL water for injection, stirring makes its dissolving, add the 4.48g active carbon, keeping temperature is 4 ℃ of stirring decolourings 30 minutes, again through 0.45 μ m filtering with microporous membrane carbon removal, add the injection water again to 2000ml, fully stir and made the solution mix homogeneously in 20 minutes, the solution for preparing carries out filtration sterilization through the microporous membrane of 0.22 μ m.Last filtrate is put into the freeze dryer charging tray, be cooled to-35 ℃ rapidly, make its primary solidification, continue to be cooled to-50 ℃ again, keep-50 ℃ freezing 4 hours, it is freezed fully, evacuation, in 10 hours, temperature is risen to 0 ℃ gradually, keep 0 ℃ of vacuum drying 11 hours, and continued to heat up, in 2 hours, rise to 30 ℃, kept 30 ℃ of vacuum dryings 7 hours, the moisture in the lactobionic acid azithromycin freeze-dried powder that obtains is 0.52%.
Experimental example 1
This experimental example is the screening experiment of activated carbon dosage and temperature, (in the table variation of lactobionic acid azithromycin content lactobionic acid azithromycin when not adding active carbon be 100% calculate), its invading the exterior 1-1 is the screening experiment of lactobionic acid azithromycin solution activated carbon dosage.
Table 1-1 lactobionic acid azithromycin solution activated carbon dosage is selected experimental result
The present invention takes all factors into consideration various factors to the adsorption test of active carbon at different temperatures lactobionic acid azithromycin solution, determines that finally the consumption of active carbon is 0.20～0.30% (g/m1).
Table 1-2 is the influence screening experiment of lactobionic acid azithromycin solution temperature to the active carbon effect.
Table 1-2 lactobionic acid azithromycin solution temperature is to the experimental result of the influence of active carbon effect
Analysis of experimental data draws from table 1-2, is controlled between 0～10 ℃ in the temperature of lactobionic acid azithromycin solution, and the effect of active carbon is best.
Experimental example 2
This experimental example be the lactobionic acid azithromycin freeze-dried powder in freezing dry process, the screening experiment of solution cooling time and pre-freeze mode during pre-freeze.Other parameter is with embodiment 1.
The screening experiment of table 2-1 pre-freeze mode
| Freezing mode | Moisture (%) | Related substance (%) | Character | Clarity |
| Elder generation's fast cooling cools to final temperature again | 0.54 | 1.82 | The white loose shape | Qualified |
| Slowly cooling cools to final temperature more earlier | 1.25 | 1.87 | The atrophy phenomenon | Defective |
| One step slowly was cooled to final temperature | 1.84 | 2.45 | The atrophy phenomenon | Defective |
| One step fast cooling is to final temperature | 1.68 | 2.38 | The white loose shape | Qualified |
By table 2-1 analysis of experimental data, the pre-freeze mode of lactobionic acid azithromycin solution has very big influence to the performance of final products, take all factors into consideration, twice temperature reduction way of the present invention, particularly, the mode that adopt first fast cooling, cools to final temperature is again carried out freezing to lactobionic acid azithromycin solution.
Table 2-2 is the Effect on Performance experiment of the control of cooling time to the freeze-dried powder product.
Table 2-2 keeps the screening experiment of cooling time
| Cooling time (h) | Moisture (%) | Related substance (%) | Character | Clarity |
| 1.0 | 1.28 | 1.92 | The atrophy phenomenon | Defective |
| 2.0 | 1.01 | 1.81 | The white loose shape | Qualified |
| 3.0 | 0.72 | 1.76 | The white loose shape | Qualified |
| 4.0 | 0.58 | 1.71 | The white loose shape | Qualified |
| 5.0 | 0.52 | 1.77 | The white loose shape | Qualified |
| 6.0 | 0.51 | 1.74 | The white loose shape | Qualified |
By table 2-2 analysis of experimental data, cooling time in the time of 6 hours, the performance of product with do not have obvious variation in 5 hours, when cooling time was relatively lacked, freeze-dried powder had the atrophy phenomenon, takes all factors into consideration, the present invention kept cooling time at 3～5 hours.
Experimental example 3
This experimental example is sublimation temperature, speed and the screening experiment of time in the lactobionic acid azithromycin freeze-dried powder freezing dry process.Other parameter is with embodiment 1.
The screening experiment of sublimation temperature in the table 3-1 freezing dry process
| Parameter | First | Second batch | The 3rd batch | The 4th batch | The 5th batch |
| Sublimation temperature (℃) | -10 | -5 | -2 | 0 | 5 |
| Moisture (%) | 1.94 | 0.73 | 0.64 | 0.56 | 0.54 |
| Related substance (%) | 1.68 | 1.79 | 1.81 | 1.88 | 2.16 |
| Clarity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Character | The white loose shape | The white loose shape | The white loose shape | The white loose shape | The spray bottle |
By table 3-1 analysis of experimental data, in dry run, when sublimation temperature is controlled at-5～0 ℃, the good combination property of freeze-dried powder.
The table 3-2 be the lactobionic acid azithromycin frozen product when lyophilization, rate of sublimation is to the influence of product.
The screening experiment of programming rate in the table 3-2 freezing dry process
| Parameter | First | Second batch | The 3rd batch | The 4th batch | The 5th batch |
| Time (h) | 7 | 9 | 11 | 12 | 14 |
| Moisture (%) | 0.97 | 0.72 | 0.65 | 0.57 | 0.79 |
| Related substance (%) | 2.78 | 1.86 | 1.73 | 1.75 | 1.69 |
| Clarity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Character | The spray bottle | The white loose shape | The white loose shape | The white loose shape | The white loose shape |
By table 3-2 analysis of experimental data, in dry run, be warmed up to the used time of sublimation temperature to be controlled at 9～12 hours the bests, The comprehensive performance is good.
Table 3-3 be the lactobionic acid azithromycin frozen product when lyophilization, the influence in time that sublimation temperature is kept to properties of product.
The screening experiment of the back temperature retention time that heats up in the table 3-3 freezing dry process
| Parameter | First | Second batch | The 3rd batch | The 4th batch | The 5th batch |
| Time (h) | 6 | 8 | 10 | 11 | 13 |
| Moisture (%) | 0.92 | 0.56 | 0.61 | 0.54 | 0.53 |
| Related substance (%) | 1.71 | 1.78 | 1.81 | 1.79 | 2.18 |
| Clarity | Qualified | Qualified | Qualified | Qualified | Defective |
| Character | The white loose shape | The white loose shape | The white loose shape | The white loose shape | The white loose shape |
By analysis of experimental data among the table 3-3, in dry run, to keep 8～11 hours in sublimation temperature, The comprehensive performance is good.
Embodiment 4
This experimental example prepares the lactobionic acid azithromycin freeze-dried powder according to the embodiment of the invention 1 freeze drying process, has investigated the dissolution velocity of this powder pin in water for injection, sees following table 4-1 for details.
The dissolution velocity test method: wait quality to get 8 bottles respectively the lactobionic acid azithromycin freeze-dried powder that makes, the dissolving method by clinical application injects 10ml water for injection respectively, with its jolting on eddy mixer.To dissolve clear and bright fully is index, calculates dissolution velocity (seeing Table 4-1).
The dissolution velocity of table 4-1 lactobionic acid azithromycin freeze-dried powder in water for injection
Experimental example 5
This experimental example is the stability test of product of the present invention.
1. accelerated test
Get three batches of these products, the simulation commercially available back is that 40 ± 2 ℃, relative humidity are to place 6 months under 75 ± 5% the condition in temperature, respectively at sampling at 0,1,2,3,6 the end of month once, measures by the high spot reviews project.See Table 5-1.
Table 5-1 lactobionic acid azithromycin for injections freeze-dried powder sample accelerated test
| Batch | Time (moon) | Character | Clarity | PH | Related substance | Indicate content |
| First | 0 1 2 3 6 | White powder white powder white powder white powder white powder | Clear and bright clear and bright | 6.71 6.70 6.71 6.68 6.66 | 1.72％ 1.76％ 1.73％ 1.75％ 1.82％ | 100.12％ 100.04％ 99.78％ 99.67％ 98.76％ |
| Second batch | 0 1 2 3 6 | White powder white powder white powder white powder white powder | Clear and bright clear and bright | 6.68 6.66 6.65 6.56 6.51 | 1.84％ 1.83％ 1.87％ 2.03％ 2.08％ | 99.92％ 99.80％ 99.74％ 98.84％ 98.29％ |
| The 3rd batch | 0 1 2 3 6 | White powder white powder white powder white powder white powder | Clear and bright clear and bright | 6.73 6.70 6.72 6.68 6.64 | 1.75％ 1.78％ 1.81％ 1.87％ 1.95％ | 100.07％ 99.87％ 99.65％ 99.19％ 98.46％ |
The result shows, this product is that 40 ± 2 ℃, relative humidity are to place 6 months under 75 ± 5% conditions in temperature, and related substance, moisture and other index have no significant change, and this product quality is basicly stable.
2. long term test
Get three batch samples respectively according to " 2005 editions second minister's phase test methods of Chinese pharmacopoeia, respectively at the every index of 3,6,9,12,24,30 sampling and measuring at the end of month, result of the test sees Table 5-2.
Table 5-2 lactobionic acid azithromycin for injections freeze-dried powder long term test
| Batch | Time (moon) | Character | Clarity | PH | Related substance | Indicate content |
| First | 0 3 6 9 12 24 30 | White powder white powder white powder white powder white powder white powder white powder | Clear and bright clear and bright clear and bright | 6.69 6.67 6.66 6.58 6.40 6.34 6.30 | 1.82％ 1.80％ 1.85％ 1.87％ 1.95％ 2.07％ 2.11％ | 99.96％ 99.92％ 99.89％ 98.93％ 98.84％ 97.46％ 97.27％ |
| Second batch | 0 | White powder | Clear and bright | 6.70 | 1.76％ | 100.25％ |
| 3 6 9 12 24 30 | White powder white powder white powder white powder white powder white powder | Clear and bright clear and bright | 6.68 6.65 6.67 6.59 6.46 6.37 | 1.78％ 1.79％ 1.85％ 1.83％ 1.96％ 2.09％ | 100.12％ 99.86％ 99.72％ 98.51％ 98.17％ 97.59％ | |
| The 3rd batch | 0 3 6 9 12 24 30 | White powder white powder white powder white powder white powder white powder white powder | Clear and bright clear and bright clear and bright | 6.68 6.64 6.43 6.39 6.35 6.22 6.14 | 1.78％ 1.85％ 1.81％ 1.94％ 1.85％ 2.08％ 2.13％ | 100.16％ 99.93％ 99.69％ 98.86％ 98.58％ 98.13％ 97.27％ |
The result shows, this product is that 25 ℃, relative humidity are to place 30 months under 60% ± 10% the condition in temperature, detects through sampling, and every index is constant substantially.
Claims (7)
1, a kind of lactobionic acid azithromycin freeze-dried powder is made up of the active component lactobionic acid azithromycin.
2, a kind of preparation method of lactobionic acid azithromycin freeze-dried powder comprises the steps:
(1) lactobionic acid azithromycin joined in the water for injection dissolve,
(2) add active carbon in the lactobionic acid azithromycin solution that step (1) obtains, aseptic filtration,
(3) with the filtrate lyophilization of step (2), promptly get the lactobionic acid azithromycin freeze-dried powder,
It is characterized in that described lyophilization is that filtrate ℃ is made it in freezer dryer internal cooling-30～-60 to solidify, and then under the fine vacuum, is warming up to 0～40 ℃ stage by stage, strict simultaneously control freeze-drying curve finally obtains the lactobionic acid azithromycin freeze-dried powder.
3, the preparation method of lactobionic acid azithromycin freeze-dried powder according to claim 2 is characterized in that, the temperature of the lactobionic acid azithromycin solution of the described adding active carbon of step (2) is 0～10 ℃, its preferred 3～5 ℃.
4, the preparation method of lactobionic acid azithromycin freeze-dried powder according to claim 2 is characterized in that, the consumption of described active carbon is 0.20～0.30% of a solution amount volume, and it is preferred 0.20～0.25% years old.
5, the preparation method of lactobionic acid azithromycin freeze-dried powder according to claim 2, it is characterized in that, refrigerating process described in the step (3) is filtrate to be cooled to-30～-40 ℃ rapidly, make it primary solidification, be cooled to-45～-60 ℃ again, keep-45～-60 ℃ freezing 3～5 hours, it is freezed fully.
6, the preparation method of lactobionic acid azithromycin freeze-dried powder according to claim 2, it is characterized in that, stating in the lactobionic acid azithromycin freezing dry process described in the step (3), after lactobionic acid azithromycin freezed fully, behind the evacuation, the temperature of the lactobionic acid azithromycin that will freeze in 9～12 hours rose to-5～0 ℃, keep-5～0 ℃ vacuum drying 8-11 hour, continue to heat up, in 2～4 hours, rise to 30～35 ℃, kept 30～35 ℃ of vacuum dryings 6～7 hours.
7, the preparation method of lactobionic acid azithromycin freeze-dried powder according to claim 2, it is characterized in that, the freeze drying process of the lactobionic acid azithromycin freeze-dried powder described in the step (3) is: lactobionic acid azithromycin filtrate is cooled to-35～-38 ℃ rapidly, it is tentatively freezed, continue to be cooled to-55～-60 ℃ again, keep-55～-60 ℃ freezing 4～4.5 hours, it is freezed fully, evacuation, the temperature of the lactobionic acid azithromycin that freezed in 11～12 hours rises to-2～0 ℃, keeps-2～0 ℃ of vacuum dryings 8～9 hours, continues to heat up, in 3～3.5 hours, rise to 30～35 ℃, kept 30～35 ℃ of vacuum dryings 6.5～7 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2008101267461A CN100528234C (en) | 2008-06-20 | 2008-06-20 | Lactobionic acid azithromycin for injections and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2008101267461A CN100528234C (en) | 2008-06-20 | 2008-06-20 | Lactobionic acid azithromycin for injections and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101327191A true CN101327191A (en) | 2008-12-24 |
| CN100528234C CN100528234C (en) | 2009-08-19 |
Family
ID=40203351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2008101267461A Expired - Fee Related CN100528234C (en) | 2008-06-20 | 2008-06-20 | Lactobionic acid azithromycin for injections and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100528234C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940555B (en) * | 2009-07-10 | 2012-02-22 | 华北制药股份有限公司 | Method for preparing azithromycin freeze-dried powder injection for injection |
| CN104419644A (en) * | 2013-09-10 | 2015-03-18 | 上海市刑事科学技术研究院 | Luminous bacteria freeze-dried preparation and preparation method thereof |
| CN104771374A (en) * | 2015-04-20 | 2015-07-15 | 北京红太阳药业有限公司 | Preparation method of lactobionic acid azithromycin freeze-dried powder injection for injection and freeze-dried powder injection prepared by preparation method |
| CN113750054A (en) * | 2021-05-27 | 2021-12-07 | 北京康仁堂药业有限公司 | Preparation method of freeze-dried powder |
-
2008
- 2008-06-20 CN CNB2008101267461A patent/CN100528234C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940555B (en) * | 2009-07-10 | 2012-02-22 | 华北制药股份有限公司 | Method for preparing azithromycin freeze-dried powder injection for injection |
| CN104419644A (en) * | 2013-09-10 | 2015-03-18 | 上海市刑事科学技术研究院 | Luminous bacteria freeze-dried preparation and preparation method thereof |
| CN104771374A (en) * | 2015-04-20 | 2015-07-15 | 北京红太阳药业有限公司 | Preparation method of lactobionic acid azithromycin freeze-dried powder injection for injection and freeze-dried powder injection prepared by preparation method |
| CN113750054A (en) * | 2021-05-27 | 2021-12-07 | 北京康仁堂药业有限公司 | Preparation method of freeze-dried powder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100528234C (en) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2781425T3 (en) | Levoisovalerylspiramycin III and its preparations, methods of preparation and uses thereof | |
| CN102133199B (en) | Doxofylline lyophilized preparation for injection and preparation method thereof | |
| CN102697795B (en) | Anti-tumor combined medicament | |
| CN100528234C (en) | Lactobionic acid azithromycin for injections and preparation method thereof | |
| CN105744957B (en) | The method for preparing the pharmaceutical composition containing mitomycin C of freeze-drying | |
| CN108938654B (en) | Pulsatillae saponin B4 injection preparation | |
| CN102302461B (en) | Dantrolene sodium freeze-dried powder injection for injection and preparation method thereof | |
| CN100506215C (en) | Cefathiamidine freeze-dried powder injection and preparing method thereof | |
| CN101584664B (en) | Cefodizime sodium proliposome preparation and preparation method thereof | |
| CN103494780B (en) | Gamithromycin composition lyophilized powder for injection and preparation method | |
| CN103610639A (en) | Polymeric micelle medicine-loaded composition containing buffer salt and preparation method thereof | |
| CN102688183B (en) | A kind of stable moxifloxacin hydrochloride injection | |
| CN1931139A (en) | Freeze dried ligustrazine hydrochloride prepn for injection and its prepn process | |
| CN103462910A (en) | Azithromycin composition for injection and preparation method thereof | |
| CN102579370A (en) | Drug combination containing levocarnitine derivatives and preparation method of drug combination | |
| CN103494779B (en) | Andrographolide powder preparation for injection and preparation method thereof | |
| CN102743342B (en) | Sodium fusidate lyophilized composition for injection | |
| CN102949353B (en) | oxaliplatin lyophilized pharmaceutical composition for injection and | |
| CN110339341A (en) | A kind of composition of Daptomycin or its salt | |
| CN104771374A (en) | Preparation method of lactobionic acid azithromycin freeze-dried powder injection for injection and freeze-dried powder injection prepared by preparation method | |
| CN104666253B (en) | Clindamycin phosphate powder for injection pharmaceutical composition and preparation method | |
| CN101254174A (en) | Freeze-dried injection containing carbazochrome sodium sulfonate and method of preparing the same | |
| CN102988402A (en) | Pharmaceutical composition containing adenosine cyclophosphate compound and preparation method of pharmaceutical composition | |
| CN103142507A (en) | Clindamycin phosphate preparation for injection and preparation method thereof | |
| CN100477998C (en) | Instant pyrobixi freeze-drying powdery injection and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HAINAN JINRUI PHARMACY STOCK CO., LTD. Free format text: FORMER NAME: HAINAN RUI JIN PHARMACEUTICAL CO. |
|
| CP03 | Change of name, title or address |
Address after: Building 8, Haikou Free Trade Zone, Nanhai Avenue, Haikou, Hainan Patentee after: Hainan Jinrui Pharmaceutical Co., Ltd. Address before: Building 8, Haikou Free Trade Zone, Nanhai Avenue, Haikou, Hainan Patentee before: Hainan Jinrui Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 Termination date: 20140620 |
|
| EXPY | Termination of patent right or utility model |